Oppenheimer Has Lowered Expectations for Teladoc Health (NYSE:TDOC) Stock Price

Teladoc Health (NYSE:TDOC) had its target price lowered by research analysts at Oppenheimer from $14.00 to $12.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the health services provider’s stock. Oppenheimer’s price objective would indicate a potential upside of 19.25% from the company’s previous close.

Several other research analysts also recently weighed in on the company. The Goldman Sachs Group started coverage on Teladoc Health in a research note on Friday, November 15th. They set a “buy” rating and a $14.00 target price for the company. Piper Sandler restated an “overweight” rating and set a $13.00 price objective (up from $11.00) on shares of Teladoc Health in a research report on Wednesday, December 4th. TD Cowen dropped their target price on shares of Teladoc Health from $9.00 to $8.00 and set a “hold” rating on the stock in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft upped their price target on shares of Teladoc Health from $10.00 to $12.00 and gave the stock a “hold” rating in a research report on Friday, November 1st. Finally, Barclays raised their price target on shares of Teladoc Health from $10.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Fourteen research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $12.08.

Teladoc Health Stock Down 0.8 %

TDOC stock opened at $10.06 on Friday. Teladoc Health has a one year low of $6.76 and a one year high of $21.74. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.69 and a current ratio of 1.73. The firm’s fifty day moving average is $10.01 and its 200 day moving average is $9.04. The firm has a market cap of $1.73 billion, a PE ratio of -1.74 and a beta of 1.01.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Wednesday, October 30th. The health services provider reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.10. The firm had revenue of $640.51 million for the quarter, compared to analysts’ expectations of $630.50 million. Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. On average, research analysts forecast that Teladoc Health will post -1.16 EPS for the current year.

Insider Buying and Selling at Teladoc Health

In other Teladoc Health news, insider Carlos Nueno sold 2,389 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $11.93, for a total transaction of $28,500.77. Following the completion of the transaction, the insider now owns 2,890 shares of the company’s stock, valued at $34,477.70. This trade represents a 45.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.95% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

Large investors have recently made changes to their positions in the stock. Clearline Capital LP raised its position in Teladoc Health by 395.6% in the second quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider’s stock valued at $42,682,000 after purchasing an additional 3,483,665 shares during the period. Point72 Asset Management L.P. raised its holdings in shares of Teladoc Health by 57.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 8,366,295 shares of the health services provider’s stock valued at $76,803,000 after buying an additional 3,063,172 shares during the period. Assenagon Asset Management S.A. acquired a new position in Teladoc Health during the 3rd quarter worth about $15,801,000. Maple Rock Capital Partners Inc. purchased a new position in Teladoc Health during the 3rd quarter valued at about $11,291,000. Finally, Invenomic Capital Management LP grew its position in Teladoc Health by 155.2% in the 3rd quarter. Invenomic Capital Management LP now owns 1,474,337 shares of the health services provider’s stock valued at $13,534,000 after acquiring an additional 896,552 shares in the last quarter. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.